title: Prevalence of active infection with Chlamydia pneumoniae and human cytomegalovirus in patients with type II diabetes mellitus.
abstract: By promoting the inflammatory process in the arterial wall, Chlamydia pneumoniae (CPN) and human cytomegalovirus (CMV) participate in the pathogenesis of cardiovascular disease (CVD). Since patients with diabetes mellitus (DM) are at high risk of CVD, we studied markers of CMV and CPN infection in DM patients as possible predictors of cardiovascular complications. The seroprevalence rates of CMV in 44 DM patients and matched controls were 74 and 88%, respectively. Compared with controls, patients showed lower titers of IgG against CMV (p < 0.001) and higher titers of genus-specific IgA against CPN (p = 0.006). The titers of genus-specific IgG and prevalence rates of type-specific anti-CPN IgA, IgG or IgM were similar in both DM patients and controls. Serological markers of either active or recent CPN infection were detected in 54% of patients and 59% of controls. However, CPN DNA was not detected in the blood of any DM patient. CMV DNA was found in the blood of 1 (2.3%) patient. The results do not indicate an increased rate of CMV or CPN infection in patients with type II DM.
authors: Centrum of Epidemiology and Microbiology, National Institute of Public Health, 100 42 Prague, Czechia. herpesvir@szu.cz
authors: K
authors: K
authors: Roubalová
authors: J
authors: J
authors: Broz
authors: D
authors: D
authors: Hrubá
authors: M
authors: M
authors: Hýblová
authors: P
authors: P
authors: Kraml
mesh_terms: D002318:Cardiovascular Diseases / Q000150:complications; D016022:Case-Control Studies; D023521:Chlamydophila Infections / Q000150:complications / Q000453:epidemiology* / Q000276:immunology; D016993:Chlamydophila pneumoniae; D003586:Cytomegalovirus Infections / Q000150:complications / Q000453:epidemiology* / Q000276:immunology; D018153:Czech Republic / Q000453:epidemiology; D048909:Diabetes Complications / Q000453:epidemiology* / Q000382:microbiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000382:microbiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016036:Seroepidemiologic Studies
references: Trends Immunol. 2004 Jan;25(1):4-7
references: 14698276
references: J Clin Microbiol. 2001 Apr;39(4):1368-77
references: 11283058
references: Clin Infect Dis. 1999 Apr;28(4):746-9
references: 10825031
references: J Clin Microbiol. 2001 May;39(5):1859-64
references: 11326004
references: Lancet. 1997 Aug 9;350(9075):430-6
references: 9259669
references: Clin Infect Dis. 2005 Feb 15;40(4):628-31
references: 15712091
references: FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
references: 10575137
references: J Gen Virol. 1993 Dec;74 ( Pt 12):2699-707
references: 8277275
references: J Immunol. 2002 Feb 1;168(3):1435-40
references: 11801686
references: J Clin Microbiol. 2003 Sep;41(9):4049-53
references: 12958224
references: Clin Infect Dis. 2005 Apr 1;40(7):990-6
references: 15824991
references: Clin Infect Dis. 2001 Aug 15;33(4):492-503
references: 11462186
references: Cent Eur J Public Health. 2003 Jun;11(2):102-6
references: 12884557